Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope® registry
- PMID: 35929089
- PMCID: PMC9525085
- DOI: 10.1093/jac/dkac235
Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope® registry
Abstract
Background: Trichoderma spp. are filamentous fungi causing invasive fungal diseases in patients with haematological malignancies and in peritoneal dialysis patients.
Objectives: To analyse clinical presentation, predisposing factors, treatment and outcome of Trichoderma infections.
Methods: A systematic literature review was conducted for published cases of invasive Trichoderma infection in PubMed until December 2021 and by reviewing the included studies' references. Cases from the FungiScope® registry were added to a combined analysis.
Results: We identified 50 invasive infections due to Trichoderma species, including 11 in the FungiScope® registry. The main underlying conditions were haematological malignancies in 19 and continuous ambulatory peritoneal dialysis (CAPD) in 10 cases. The most prevalent infection sites were lung (42%) and peritoneum (22%). Systemic antifungal therapy was administered in 42 cases (84%), mostly amphotericin B (n = 27, lipid-based formulation 13/27) and voriconazole in 15 cases (30%). Surgical interventions were performed in 13 cases (26%). Overall mortality was 48% (n = 24) and highest for allogeneic HSCT and solid organ transplantation (SOT) recipients [80% (4/5) and 77% (7/9), respectively]. In patients treated with amphotericin B, voriconazole and caspofungin, mortality was 55% (15/27), 46% (7/15) and 28% (2/7), respectively. Three out of four patients treated with a combination therapy of voriconazole and caspofungin survived.
Conclusions: Despite treatment with antifungal therapies and surgery, invasive Trichoderma infections are life-threatening complications in immunocompromised patients, especially after HSCT and SOT. In addition, Trichoderma spp. mainly affect the lungs in patients with haematological malignancies and the peritoneum in CAPD patients.
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Figures
References
-
- Alanio A, Brethon B, Feuilhade de Chauvin Met al. . Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin. Clin Infect Dis 2008; 46: e116–8. - PubMed
-
- Druzhinina IS, Kopchinskiy AG, Kubicek CP. The first 100 Trichoderma species characterized by molecular data. Mycoscience 2006; 47: 55–64.
-
- Druzhinina IS, Seidl-Seiboth V, Herrera-Estrella Aet al. . Trichoderma: the genomics of opportunistic success. Nat Rev Microbiol 2011; 9: 749–59. - PubMed
-
- Chouaki T, Lavarde V, Lachaud Let al. . Invasive infections due to Trichoderma species: report of 2 cases, findings of in vitro susceptibility testing, and review of the literature. Clin Infect Dis 2002; 35: 1360–7. - PubMed
-
- De Miguel D, Gómez P, González Ret al. . Nonfatal pulmonary Trichoderma viride infection in an adult patient with acute myeloid leukemia: report of one case and review of the literature. Diagn Microbiol Infect Dis 2005; 53: 33–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
